The estimated Net Worth of John P Engels is at least 1.31 百万$ dollars as of 7 October 2016. John Engels owns over 4,000 units of Axogen stock worth over 1,307,084$ and over the last 13 years John sold AXGN stock worth over 0$.
John has made over 1 trades of the Axogen stock since 2016, according to the Form 4 filled with the SEC. Most recently John bought 4,000 units of AXGN stock worth 30,000$ on 7 October 2016.
The largest trade John's ever made was buying 4,000 units of Axogen stock on 7 October 2016 worth over 30,000$. On average, John trades about 667 units every 0 days since 2011. As of 7 October 2016 John still owns at least 98,425 units of Axogen stock.
You can see the complete history of John Engels stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O AXOGEN, INC., 13859 PROGRESS BOULEVARD, SUITE 100, ALACHUA, FL, 32615.
Over the last 13 years, insiders at Axogen have traded over 73,805,978$ worth of Axogen stock and bought 504,297 units worth 3,119,117$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Guido J Neels、Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of 455,132$. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth 158,085$.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: